Difficulties in Diagnosing Fabry Disease in Patients with Unexplained Left Ventricular Hypertrophy (LVH): Is the Novel GLA Gene Mutation a Pathogenic Mutation or Polymorphism?

1. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003 Feb 18;138(4):338–46. doi: 10.7326/0003-4819-138-4-200302180-00014. DesnickRJ BradyR BarrangerJ CollinsAJ GermainDP GoldmanM Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy Ann Intern Med 2003 Feb 18 138 4 338 46 10.7326/0003-4819-138-4-200302180-00014 Open DOISearch in Google Scholar

2. Pinto LL, Vieira TA, Giugliani R, Schwartz IV. Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review. Orphanet J Rare Dis. 2010 May 28;5:14. doi: 10.1186/1750-1172-5-14. PintoLL VieiraTA GiuglianiR SchwartzIV Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review Orphanet J Rare Dis 2010 May 28 5 14 10.1186/1750-1172-5-14 Open DOISearch in Google Scholar

3. Garman SC, Garboczi DN. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol. 2004 Mar 19;337(2):319–35. doi: 10.1016/j.jmb.2004.01.035. GarmanSC GarbocziDN The molecular defect leading to Fabry disease: structure of human alpha-galactosidase J Mol Biol 2004 Mar 19 337 2 319 35 10.1016/j.jmb.2004.01.035 Open DOISearch in Google Scholar

4. Kampmann C, Baehner F, Whybra C, Martin C, Wiethoff CM, Ries M, et al. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol. 2002 Nov 6;40(9):1668–74. doi: 10.1016/s0735-1097(02)02380-x. KampmannC BaehnerF WhybraC MartinC WiethoffCM RiesM Cardiac manifestations of Anderson-Fabry disease in heterozygous females J Am Coll Cardiol 2002 Nov 6 40 9 1668 74 10.1016/s0735-1097(02)02380-x Open DOISearch in Google Scholar

5. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004 Mar;34(3):236–42. doi: 10.1111/j.1365-2362.2004.01309.x. MehtaA RicciR WidmerU DehoutF Garcia de LorenzoA KampmannC Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey Eur J Clin Invest 2004 Mar 34 3 236 42 10.1111/j.1365-2362.2004.01309.x Open DOISearch in Google Scholar

6. Morrissey RP, Philip KJ, Schwarz ER. Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy. Cardiovasc J Afr. 2011 Jan–Feb;22(1):38–44. MorrisseyRP PhilipKJ SchwarzER Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy Cardiovasc J Afr 2011 Jan–Feb 22 1 38 44 Search in Google Scholar

7. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999 Jan 20;281(3):249–54. doi: 10.1001/jama.281.3.249. MeiklePJ HopwoodJJ ClagueAE CareyWF Prevalence of lysosomal storage disorders JAMA 1999 Jan 20 281 3 249 54 10.1001/jama.281.3.249 Open DOISearch in Google Scholar

8. Barba-Romero MÁ, Rivera-Gallego A, Pintos-Morell G; Spanish FOS-Study Group. Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS). Int J Clin Pract. 2011 Aug;65(8):903–10. doi: 10.1111/j.1742-1241.2011.02695.x. Barba-RomeroMÁ Rivera-GallegoA Pintos-MorellG Spanish FOS-Study Group Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS) Int J Clin Pract 2011 Aug 65 8 903 10 10.1111/j.1742-1241.2011.02695.x Open DOISearch in Google Scholar

9. Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE. Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet. 2010 Apr;47(4):217–22. doi: 10.1136/jmg.2009.072116. LinthorstGE BouwmanMG WijburgFA AertsJM PoorthuisBJ HollakCE Screening for Fabry disease in high-risk populations: a systematic review J Med Genet 2010 Apr 47 4 217 22 10.1136/jmg.2009.072116 Open DOISearch in Google Scholar

10. Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, et al; FOS Investigators. Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet. 2009 Aug;46(8):548–52. doi: 10.1136/jmg.2008.065904. MehtaA ClarkeJT GiuglianiR ElliottP LinhartA BeckM FOS Investigators Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey J Med Genet 2009 Aug 46 8 548 52 10.1136/jmg.2008.065904 Open DOISearch in Google Scholar

11. Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med. 2009 Nov;11(11):790–6. doi: 10.1097/GIM.0b013e3181bb05bb. WaldekS PatelMR BanikazemiM LemayR LeeP Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry Genet Med 2009 Nov 11 11 790 6 10.1097/GIM.0b013e3181bb05bb Open DOISearch in Google Scholar

12. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshida A, Kuriyama M, Hayashibe H, Sakuraba H, et al. An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med. 1995 Aug 3;333(5):288–93. doi: 10.1056/NEJM199508033330504. NakaoS TakenakaT MaedaM KodamaC TanakaA TaharaM YoshidaA KuriyamaM HayashibeH SakurabaH An atypical variant of Fabry’s disease in men with left ventricular hypertrophy N Engl J Med 1995 Aug 3 333 5 288 93 10.1056/NEJM199508033330504 Open DOISearch in Google Scholar

13. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233–70. doi: 10.1093/ehjci/jev014. LangRM BadanoLP Mor-AviV AfilaloJ ArmstrongA ErnandeL Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging Eur Heart J Cardiovasc Imaging 2015 Mar 16 3 233 70 10.1093/ehjci/jev014 Open DOISearch in Google Scholar

14. Niemann M, Rolfs A, Störk S, Bijnens B, Breunig F, Beer M, et al. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet. 2014 Feb;7(1):8–16. doi: 10.1161/CIRCGENETICS.113.000249. NiemannM RolfsA StörkS BijnensB BreunigF BeerM Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease Circ Cardiovasc Genet 2014 Feb 7 1 8 16 10.1161/CIRCGENETICS.113.000249 Open DOISearch in Google Scholar

15. Niemann M, Rolfs A, Giese A, Mascher H, Breunig F, Ertl G, Wanner C, Weidemann F. Lyso-Gb3 Indicates that the Alpha-Galactosidase A Mutation D313Y is not Clinically Relevant for Fabry Disease. JIMD Rep. 2013;7:99–102. doi: 10.1007/8904_2012_154. NiemannM RolfsA GieseA MascherH BreunigF ErtlG WannerC WeidemannF Lyso-Gb3 Indicates that the Alpha-Galactosidase A Mutation D313Y is not Clinically Relevant for Fabry Disease JIMD Rep. 2013 7 99 102 10.1007/8904_2012_154 Open DOISearch in Google Scholar

16. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010 Nov 22;5:30. doi: 10.1186/1750-1172-5-30 GermainDP Fabry disease Orphanet J Rare Dis 2010 Nov 22 5 30 10.1186/1750-1172-5-30 Open DOISearch in Google Scholar

17. Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation. 2004 Aug 31;110(9):1047–53. doi: 10.1161/01.CIR.0000139847.74101.03. ChimentiC PieroniM MorganteE AntuzziD RussoA RussoMA Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy Circulation 2004 Aug 31 110 9 1047 53 10.1161/01.CIR.0000139847.74101.03 Open DOISearch in Google Scholar

18. Havndrup O, Christiansen M, Stoevring B, Jensen M, Hoffman-Bang J, Andersen PS, et al. Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women. Eur J Heart Fail. 2010 Jun;12(6):535–40. doi: 10.1093/eurjhf/hfq073. HavndrupO ChristiansenM StoevringB JensenM Hoffman-BangJ AndersenPS Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women Eur J Heart Fail 2010 Jun 12 6 535 40 10.1093/eurjhf/hfq073 Open DOISearch in Google Scholar

19. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002 Mar 26;105(12):1407–11. doi: 10.1161/01.cir.0000012626.81324.38. SachdevB TakenakaT TeraguchiH TeiC LeeP McKennaWJ Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy Circulation 2002 Mar 26 105 12 1407 11 10.1161/01.cir.0000012626.81324.38 Open DOISearch in Google Scholar

20. Ommen SR, Nishimura RA, Edwards WD. Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy? Heart. 2003 Aug;89(8):929–30. doi: 10.1136/heart.89.8.929. OmmenSR NishimuraRA EdwardsWD Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy? Heart 2003 Aug 89 8 929 30 10.1136/heart.89.8.929 Open DOISearch in Google Scholar

21. Monserrat L, Gimeno-Blanes JR, Marín F, Hermida-Prieto M, García-Honrubia A, Pérez I, et al. Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2007 Dec 18;50(25):2399–403. doi: 10.1016/j.jacc.2007.06.062. MonserratL Gimeno-BlanesJR MarínF Hermida-PrietoM García-HonrubiaA PérezI Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy J Am Coll Cardiol 2007 Dec 18 50 25 2399 403 10.1016/j.jacc.2007.06.062 Open DOISearch in Google Scholar

22. Elliott P, Baker R, Pasquale F, Quarta G, Ebrahim H, Mehta AB, et al; ACES study group. Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey. Heart. 2011 Dec;97(23):1957–60. doi: 10.1136/heartjnl-2011-300364. ElliottP BakerR PasqualeF QuartaG EbrahimH MehtaAB ACES study group Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey Heart 2011 Dec 97 23 1957 60 10.1136/heartjnl-2011-300364 Open DOISearch in Google Scholar

23. Hagège AA, Caudron E, Damy T, Roudaut R, Millaire A, Etchecopar-Chevreuil C, et al; FOCUS study investigators. Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study. Heart. 2011 Jan;97(2):131–6. doi: 10.1136/hrt.2010.200188. HagègeAA CaudronE DamyT RoudautR MillaireA Etchecopar-ChevreuilC FOCUS study investigators Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study Heart 2011 Jan 97 2 131 6 10.1136/hrt.2010.200188 Open DOISearch in Google Scholar

24. Mawatari K, Yasukawa H, Oba T, Nagata T, Togawa T, Tsukimura T, et al. Screening for Fabry disease in patients with left ventricular hypertrophy. Int J Cardiol. 2013 Aug 10;167(3):1059–61. doi: 10.1016/j.ijcard.2012.10.076. MawatariK YasukawaH ObaT NagataT TogawaT TsukimuraT Screening for Fabry disease in patients with left ventricular hypertrophy Int J Cardiol 2013 Aug 10 167 3 1059 61 10.1016/j.ijcard.2012.10.076 Open DOISearch in Google Scholar

25. Terryn W, Deschoenmakere G, De Keyser J, Meersseman W, Van Biesen W, Wuyts B, et al. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy. Int J Cardiol. 2013 Sep 10;167(6):2555–60. doi: 10.1016/j.ijcard.2012.06.069. TerrynW DeschoenmakereG De KeyserJ MeerssemanW Van BiesenW WuytsB Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy Int J Cardiol 2013 Sep 10 167 6 2555 60 10.1016/j.ijcard.2012.06.069 Open DOISearch in Google Scholar

26. Palecek T, Honzikova J, Poupetova H, Vlaskova H, Kuchynka P, Golan L, et al. Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS). J Inherit Metab Dis. 2014 May;37(3):455–60. doi: 10.1007/s10545-013-9659-2. PalecekT HonzikovaJ PoupetovaH VlaskovaH KuchynkaP GolanL Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS) J Inherit Metab Dis 2014 May 37 3 455 60 10.1007/s10545-013-9659-2 Open DOISearch in Google Scholar

27. Baptista A, Magalhães P, Leão S, Carvalho S, Mateus P, Moreira I. Screening for Fabry disease in left ventricular hypertrophy: documentation of a novel mutation. Arq Bras Cardiol. 2015 Aug;105(2):139–44. doi: 10.5935/abc.20150090. BaptistaA MagalhãesP LeãoS CarvalhoS MateusP MoreiraI Screening for Fabry disease in left ventricular hypertrophy: documentation of a novel mutation Arq Bras Cardiol 2015 Aug 105 2 139 44 10.5935/abc.20150090 Open DOISearch in Google Scholar

28. Vieitez I, Souto-Rodriguez O, Fernandez-Mosquera L, San Millan B, Teijeira S, Fernandez-Martin J, et al. Fabry disease in the Spanish population: observational study with detection of 77 patients. Orphanet J Rare Dis. 2018 Apr 10;13(1):52. doi: 10.1186/s13023-018-0792-8. VieitezI Souto-RodriguezO Fernandez-MosqueraL San MillanB TeijeiraS Fernandez-MartinJ Fabry disease in the Spanish population: observational study with detection of 77 patients Orphanet J Rare Dis 2018 Apr 10 13 1 52 10.1186/s13023-018-0792-8 Open DOISearch in Google Scholar

29. Maron MS, Xin W, Sims KB, Butler R, Haas TS, Rowin EJ, et al. Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy. Am J Med. 2018 Feb;131(2):200.e1–200.e8. doi: 10.1016/j.amjmed.2017.09.010. MaronMS XinW SimsKB ButlerR HaasTS RowinEJ Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy Am J Med 2018 Feb 131 2 200.e1 200.e8 10.1016/j.amjmed.2017.09.010 Open DOISearch in Google Scholar

30. Kim WS, Kim HS, Shin J, Park JC, Yoo HW, Takenaka T, et al. Prevalence of Fabry Disease in Korean Men with Left Ventricular Hypertrophy. J Korean Med Sci. 2019 Feb 15;34(7):e63. doi: 10.3346/jkms.2019.34.e63. KimWS KimHS ShinJ ParkJC YooHW TakenakaT Prevalence of Fabry Disease in Korean Men with Left Ventricular Hypertrophy J Korean Med Sci 2019 Feb 15 34 7 e63 10.3346/jkms.2019.34.e63 Open DOISearch in Google Scholar

31. Oder D, Üçeyler N, Liu D, Hu K, Petritsch B, Sommer C, et al. Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y. BMJ Open. 2016 Apr 8;6(4):e010422. doi: 10.1136/bmjopen-2015-010422. OderD ÜçeylerN LiuD HuK PetritschB SommerC Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y BMJ Open 2016 Apr 8 6 4 e010422 10.1136/bmjopen-2015-010422 Open DOISearch in Google Scholar

32. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore). 2002 Mar;81(2):122–38. doi: 10.1097/00005792-200203000-00003. BrantonMH SchiffmannR SabnisSG MurrayGJ QuirkJM AltarescuG Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course Medicine (Baltimore) 2002 Mar 81 2 122 38 10.1097/00005792-200203000-00003 Open DOISearch in Google Scholar

33. Ferreira S, Ortiz A, Germain DP, Viana-Baptista M, Caldeira-Gomes A, Camprecios M, et al. The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies. Mol Genet Metab. 2015 Feb;114(2):248–58. doi: 10.1016/j.ymgme.2014.11.004. FerreiraS OrtizA GermainDP Viana-BaptistaM Caldeira-GomesA CampreciosM The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies Mol Genet Metab 2015 Feb 114 2 248 58 10.1016/j.ymgme.2014.11.004 Open DOISearch in Google Scholar

34. Eng CM, Desnick RJ. Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene. Hum Mutat. 1994;3(2):103–11. doi: 10.1002/humu.1380030204. EngCM DesnickRJ Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene Hum Mutat. 1994 3 2 103 11 10.1002/humu.1380030204 Open DOISearch in Google Scholar

35. Eng CM, Ashley GA, Burgert TS, Enriquez AL, D’Souza M, Desnick RJ. Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med. 1997 Mar;3(3):174–82. EngCM AshleyGA BurgertTS EnriquezAL D’SouzaM DesnickRJ Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes Mol Med 1997 Mar 3 3 174 82 Search in Google Scholar

36. Van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH, Linthorst GE, et al. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014 Jan;51(1):1–9. doi: 10.1136/jmedgenet-2013-101857. Van der TolL SmidBE PoorthuisBJ BiegstraatenM DeprezRH LinthorstGE A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance J Med Genet 2014 Jan 51 1 1 9 10.1136/jmedgenet-2013-101857 Open DOISearch in Google Scholar

37. Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta A; FOS European Investigators. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey. Clin J Pain. 2007 Jul–Aug;23(6):535–42. doi: 10.1097/AJP.0b013e318074c986. HoffmannB BeckM Sunder-PlassmannG BorsiniW RicciR MehtaA FOS European Investigators Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey Clin J Pain 2007 Jul–Aug 23 6 535 42 10.1097/AJP.0b013e318074c986 Open DOISearch in Google Scholar